Eagle Pharmaceuticals, Inc (EGRX)

Etorro trading 970x250
Eagle Pharmaceuticals, Inc (EGRX) Logo

About Eagle Pharmaceuticals, Inc

Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey. Address: 50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677

Eagle Pharmaceuticals, Inc News and around…

Latest news about Eagle Pharmaceuticals, Inc (EGRX) common stock and company :

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
01 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
28 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

We Think Eagle Pharmaceuticals (NASDAQ:EGRX) Can Manage Its Debt With Ease
22 Sep, 2021 Yahoo! Finance

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021
07 Sep, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) will host an investor event, led by Scott Tarriff, Chief Executive Officer, and Judi Ng-Cashin, Chief Medical Officer, and will feature other guest speakers, to discuss the CAL02 opportunity, the current treatment landscape and the unmet medical need in treating patients with severe pneumonia as follows:

Eagle Pharmaceuticals to Present at September Healthcare Conferences
01 Sep, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at two upcoming investor conferences as follows:

Company News for Sep 1, 2021
01 Sep, 2021 Yahoo! Finance

Companies in the news are: NTES, SONN, EGRX, ZEV

The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
01 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

55 Biggest Movers From Yesterday
01 Sep, 2021 FinancialContent

Gainers Unico American Corporation (NASDAQ: UNAM) shares gained 59% to close at $4.15 on Tuesday. Elys Game Technology, Corp. ...

5 Top Stock Gainers for Tuesday: Virgin Galactic, Digital Turbine
31 Aug, 2021 Yahoo! Finance

Virgin Galactic, Digital Turbine, AC Immune SA, Spok Holdings and Eagle Pharmaceuticals are five top stock gainers for Tuesday.

33 Stocks Moving In Tuesday's Mid-Day Session
31 Aug, 2021 FinancialContent

Gainers AC Immune SA (NASDAQ: ACIU) shares jumped 68.4% to $11.77. AC Immune and its collaborating partner Genentech, part of ...

Eagle Pharmaceuticals Wins Vasopressin Patent Trial
31 Aug, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product does not infringe any of the patents Par asserted against the Company.

Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise
31 Aug, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,103,483, entitled “Formulations of Bendamustine.” Eagle is submitting the ‘483 patent for listing in the U.S. Food and Drug Administration’s Orange Book for both BENDEKA® and BELRAPZO®.

The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
25 Aug, 2021 FinancialContent

ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the T
25 Aug, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has entered into a worldwide licensing agreement with Combioxin SA (“Combioxin”), a clinical-stage biotechnology company based in Epalinges, Switzerland, for the commercial rights to CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs.

Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia
25 Aug, 2021 Yahoo! Finance

WOODCLIFF LAKE, N.J., August 25, 2021--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that it has entered into a worldwide licensing agreement with Combioxin SA ("Combioxin"), a clinical-stage biotechnology company based in Epalinges, Switzerland, for the commercial rights to CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs.

Eagle Pharmaceuticals, inc (EGRX) Q2 2021 Earnings Call Transcript
09 Aug, 2021 FinancialContent

EGRX earnings call for the period ending June 30, 2021.

Eagle Pharmaceuticals In-Licenses US Rights For Emergency Hospital Product, Q2 Earnings Beat Consensus
09 Aug, 2021 FinancialContent

Eagle Pharmaceuticals Inc(NASDAQ: EGRX) hasentered into a licensing agreementwith AOP Orphan Pharmaceuticals GmbH ...

Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Surpass Estimates
09 Aug, 2021 Yahoo! Finance

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 5.68% and 1.74%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Recap: Eagle Pharmaceuticals Q2 Earnings
09 Aug, 2021 FinancialContent

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) were unchanged after the company reported Q2 results. Quarterly ...

Eagle Pharmaceuticals Reports Second Quarter 2021 Results
09 Aug, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and six months ended June 30, 2021.

Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker
09 Aug, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH (“AOP Orphan”), a privately owned Austrian company devoted to the treatment of rare and special diseases, for the commercial rights to its product, Landiolol in the United States. Landiolol, a leading hospital emergency use product, is currently approved in Europe for the treatment of non-compensatory sinus tachycardia and tachycardic supraventricular arrhythmias. The Company will support the submission of a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) seeking approval for Landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia (“SVT”), including atrial fibrillation and atrial flutter.

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

Eagle Pharmaceuticals (EGRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
02 Aug, 2021 Yahoo! Finance

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Were Hedge Funds Right About Eagle Pharmaceuticals Inc (EGRX)?
29 Jul, 2021 Yahoo! Finance

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 900 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]

Eagle Pharmaceuticals to Host Second Quarter 2021 Financial Results on August 9, 2021
28 Jul, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 second quarter financial results on Monday, August 9, 2021, before the market opens.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
14 Jul, 2021 Yahoo! Finance

Most readers would already be aware that Eagle Pharmaceuticals' (NASDAQ:EGRX) stock increased significantly by 17% over...

Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin
24 Jun, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug and Administration (“FDA”) has maintained Priority Review for the Company’s Abbreviated New Drug Application (“ANDA”) for vasopressin. The Company’s response to the CRL was submitted on June 15, 2021. The FDA has assigned a GDUFA date of December 15, 2021, and the Company expects a commercial launch prior to year-end.

Eagle Pharmaceuticals: Return On Capital Employed Insights
22 Jun, 2021 FinancialContent

During Q1, Eagle Pharmaceuticals (NASDAQ:EGRX) brought in sales totaling $41.25 million. However, earnings decreased 138.53%, resulting ...

Eagle Pharmaceuticals, Inc (EGRX) is a NASDAQ Common Stock listed in , ,

970x250